Likewise, we observed a substantial (∼75–95%) decrease in viability of human cancer cells harboring other aggregation-prone p53 mutants (R248W: COLO 320DM and NCI-H1770; R248Q: HCC70 and OVCAR-3; R175H: LS123; R273H: HT-29 and ARH-77; Y220C: NCI-H748 and NCI-H2342; and R280K: MDA-MB-231) following treatment with ADH-6 (Supplementary Fig. 11f). This evidence concerns the gene ADH6 and cancer.